Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770626 | 1.00 | PRKCA (0.36) | PRKCAMMP1MMP2MMP3MMP9 | |
| SCHEMBL2036048 | 0.93 | PRKCA (0.35) | PRKCATDP1ALDH1A1 | |
| SCHEMBL28766201 | 0.89 | F7 (0.41) | PRKCADGKAALDH1A1 | |
| SCHEMBL28588909 | 0.89 | F7 (0.41) | PRKCADGKAALDH1A1 | |
| SCHEMBL17075354 | 0.85 | PRKCA (0.37) | PRKCAMMP1MMP2MMP3MMP9 | |
| SCHEMBL17075355 | 0.85 | PRKCA (0.37) | PRKCAMMP1MMP2MMP3MMP9 | |
| SCHEMBL5898821 | 0.82 | MME (0.32) | — | |
| SCHEMBL5898822 | 0.82 | MME (0.32) | — | |
| SCHEMBL873462 | 0.80 | NAAA (0.42) | TSHRTDP1DGKATAS1R3TAS1R1 | |
| SCHEMBL2039597 | 0.80 | NAAA (0.42) | TSHRTDP1DGKATAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4435080-B1 | A PROCESS OF MAKING A SALTED SPRAY-DRIED PERFUME MICROCAPSULE PARTICLE | PROCTER & GAMBLE (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12371642-B2 | Benefit agent containing delivery particle | THE PROCTER & GAMBLE COMPANY (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3955900-B1 | POLYMERIC CAPSULES | PROCTER & GAMBLE (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240316523-A1 | PROCESS OF MAKING A SALTED SPRAY-DRIED PERFUME MICROCAPSULE PARTICLE | PROCTER & GAMBLE COMPANY, THE | 2024-09-26 | — | — | US | disclosed |
| EP-4435080-A1 | A PROCESS OF MAKING A SALTED SPRAY-DRIED PERFUME MICROCAPSULE PARTICLE | The Procter & Gamble Company (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-3596192-B1 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE SLURRIES | PROCTER & GAMBLE (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117426473-A | Preparation method of salix mongolica water extract, preparation method of salix mongolica flavor seasoning and application of salix mongolica flavor seasoning | 黄山学院 | 2024-01-23 | — | — | CN | disclosed |
| US-20230313084-A1 | BENEFIT AGENT CONTAINING DELIVERY PARTICLE | PROCTER & GAMBLE (US) | 2023-10-05 | — | — | US | disclosed |
| EP-3664900-B1 | PHOTOSENSITIVE MICROCAPSULES | PROCTER & GAMBLE INT OPERATIONS SA (CH) | 2023-08-23 | — | — | EP | disclosed |
| US-11713437-B2 | Benefit agent containing delivery particle slurries | THE PROCTER & GAMBLE COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-8759275-B2 | High-efficiency perfume capsules | THE PROCTOR & GAMBLE COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130316937-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2013-11-28 | — | — | US | disclosed |
| EP-2468239-B1 | Encapsulates | PROCTER & GAMBLE INTERNAT OPERATIONS SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8524650-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130039962-A1 | ENCAPSULATES | ENCAPSYS, LLC | 2013-02-14 | — | — | US | disclosed |
| EP-2468239-A1 | Encapsulates | Procter & Gamble International Operations SA (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20120152268-A1 | ENCAPSULATES | PROCTER & GAMBLE COMPANY, THE | 2012-06-21 | — | — | US | disclosed |
| US-20110152147-A1 | ENCAPSULATES | PROCTER & GAMBLE COMPANY, THE | 2011-06-23 | — | — | US | disclosed |
| US-20110152146-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY | 2011-06-23 | — | — | US | disclosed |
| US-20110111999-A1 | HIGH-EFFICIENCY PERFUME CAPSULES | THE PROCTER & GAMBLE COMPANY | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039962-A1 | ENCAPSULATES | ABCB4, PPIB, FLNB | PRKCA 4376/4885MMP1 2347/4885MMP2 4269/4885 |
| US-20110111999-A1 | HIGH-EFFICIENCY PERFUME CAPSULES | PLIN5, PORCN, PIGS | PRKCA 3328/4885MMP1 1083/4885MMP2 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.